G1 THERAPEUTICS (NASDAQ:GTHX) – Research analysts at Wedbush cut their Q3 2017 earnings per share (EPS) estimates for shares of G1 THERAPEUTICS in a research report issued on Thursday. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.58) per share for the quarter, down from their previous forecast of ($0.51). Wedbush currently has a “Outperform” rating and a $31.00 target price on the stock. Wedbush also issued estimates for G1 THERAPEUTICS’s Q4 2017 earnings at ($0.61) EPS, FY2018 earnings at ($2.27) EPS, FY2019 earnings at ($2.43) EPS, FY2020 earnings at ($2.18) EPS and FY2021 earnings at ($1.38) EPS.

G1 THERAPEUTICS (NASDAQ:GTHX) last posted its earnings results on Wednesday, August 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.48. COPYRIGHT VIOLATION NOTICE: “Q3 2017 Earnings Estimate for G1 THERAPEUTICS Issued By Wedbush (GTHX)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/14/q3-2017-earnings-estimate-for-g1-therapeutics-issued-by-wedbush-gthx.html.

A number of other research firms have also weighed in on GTHX. Cowen and Company started coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They issued an “outperform” rating and a $31.00 target price for the company. Needham & Company LLC started coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They issued a “buy” rating and a $34.00 target price for the company. Finally, J P Morgan Chase & Co started coverage on G1 THERAPEUTICS in a research note on Monday, June 12th. They issued an “overweight” rating and a $23.00 target price for the company.

Shares of G1 THERAPEUTICS (GTHX) opened at 12.77 on Monday. G1 THERAPEUTICS has a 52 week low of $12.04 and a 52 week high of $20.60. The stock has a 50 day moving average price of $15.28 and a 200 day moving average price of $16.19. The firm’s market cap is $18.90 million.

Large investors have recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in G1 THERAPEUTICS during the second quarter worth $34,093,000. Franklin Resources Inc. acquired a new position in shares of G1 THERAPEUTICS during the second quarter worth about $10,651,000. Laurion Capital Management LP acquired a new position in shares of G1 THERAPEUTICS during the second quarter worth about $3,488,000. Chartwell Investment Partners LLC acquired a new position in shares of G1 THERAPEUTICS during the second quarter worth about $1,538,000. Finally, Vanguard Group Inc. acquired a new position in shares of G1 THERAPEUTICS during the second quarter worth about $1,291,000. 4.57% of the stock is owned by institutional investors.

In related news, insider Ra Capital Healthcare Fund Lp bought 400,000 shares of the stock in a transaction dated Monday, May 22nd. The stock was bought at an average price of $15.00 per share, with a total value of $6,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Fredric N. Eshelman bought 300,000 shares of the stock in a transaction dated Monday, May 22nd. The stock was bought at an average cost of $15.00 per share, with a total value of $4,500,000.00. The disclosure for this purchase can be found here. In the last three months, insiders bought 833,333 shares of company stock valued at $12,499,995.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Earnings History and Estimates for G1 THERAPEUTICS (NASDAQ:GTHX)

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.